E-LIB Suche - Ergebnisse für: Jones, Mark E.

1

1699. Safety and Outcomes of Isavuconazonium Sulfate for th..:

Arrieta, Antonio C ; Segers, Heidi ; Deville, Jaime G...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

2

2162. In Vitro Antimicrobial Activity of Ceftobiprole again..:

Duncan, Leonard R ; Castanheira, Mariana ; Smart, Jennifer..
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

3

2561. Population Pharmacokinetic Analyses for Ceftobiprole ..:

Cammarata, Anthony P ; Litherland, Karine ; Safir, M Courtney...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

4

2173. Activity of Ceftobiprole Against Enterococcus faecali..:

Mendes, Rodrigo E ; Duncan, Leonard R ; Sader, Helio S...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

5

1946. In Vitro Activity of Ceftobiprole against Staphylococ..:

Duncan, Leonard R ; Castanheira, Mariana ; Smart, Jennifer..
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

6

2785. Characterization of Methicillin-resistant Staphylococ..:

Mendes, Rodrigo E ; Duncan, Leonard R ; Kimbrough, John H...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

7

2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attain..:

Bhavnani, Sujata M ; Hammel, Jeffrey P ; Rinaldo, Anthony J...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

8

2532. Pharmacokinetic-Pharmacodynamic Analyses for Ceftobip..:

Bhavnani, Sujata M ; Hammel, Jeffrey P ; Liolios, Kathryn...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

9

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attain..:

Bhavnani, Sujata M ; Hammel, Jeffrey P ; Rinaldo, Anthony J...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

10

Safety, Tolerability, and Population Pharmacokinetics of In..:

Arrieta, Antonio C. ; Neely, Michael ; Day, J. Christopher...
Antimicrobial Agents and Chemotherapy. 65 (2021) 8 - p. , 2021

Link: https://doi.org/10.1128/..

11

Ceftobiprole Versus Daptomycin inStaphylococcus AureusBacte..:

Hamed, Kamal ; Engelhardt, Marc ; Jones, Mark E...
Future Microbiology. 15 (2020) 1 - p. 35-48 , 2020

Link: https://doi.org/10.2217/..

12

Near-Field Remote Sensing of Surface Velocity and River Dis..:

Fulton, John W. ; Mason, Christopher A. ; Eggleston, John R....
Remote Sensing. 12 (2020) 8 - p. 1296 , 2020

Link: https://doi.org/10.3390/..

13

Ceftobiprole Compared With Vancomycin Plus Aztreonam in the..:

Overcash, J Scott ; Kim, Charles ; Keech, Richard...
Clinical Infectious Diseases. 73 (2020) 7 - p. e1507-e1517 , 2020

Link: https://doi.org/10.1093/..

14

Evaluation of reagents used to coat the hollow-fiber biorea..:

Frank, Nathan D. ; Jones, Mark E. ; Vang, Boah.
Materials Science and Engineering: C. 96 (2019) - p. 77-85 , 2019

Link: https://doi.org/10.1016/..

15

Outcomes by MIC Values for Patients Treated with Isavuconaz..:

Andes, David R. ; Ghannoum, Mahmoud A. ; Mukherjee, Pranab K....
Antimicrobial Agents and Chemotherapy. 63 (2019) 1 - p. , 2019

Link: https://doi.org/10.1128/..